Compare CRAI & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | CERT |
|---|---|---|
| Founded | 1965 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 1998 | 2020 |
| Metric | CRAI | CERT |
|---|---|---|
| Price | $184.44 | $7.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $245.00 | $11.67 |
| AVG Volume (30 Days) | 119.1K | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | 20.77 | ★ 87.50 |
| EPS | ★ 8.14 | N/A |
| Revenue | ★ $751,583,000.00 | $418,838,000.00 |
| Revenue This Year | $7.82 | $4.18 |
| Revenue Next Year | $5.14 | $5.39 |
| P/E Ratio | $23.35 | ★ N/A |
| Revenue Growth | ★ 9.33 | 8.75 |
| 52 Week Low | $132.17 | $4.45 |
| 52 Week High | $227.29 | $13.88 |
| Indicator | CRAI | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 75.58 | 74.97 |
| Support Level | $172.05 | $8.03 |
| Resistance Level | $194.94 | $9.80 |
| Average True Range (ATR) | 8.53 | 0.34 |
| MACD | 1.67 | 0.08 |
| Stochastic Oscillator | 90.17 | 91.55 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.